For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

A study conducted at the University of Eastern Finland revealed that a recently described T cell subset may have a central role in the development of type 1 diabetes. These so called follicular T ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success.

Percentage of γδ T cells increased in multiple myeloma patients. (A) gating for γδ T cells in multiple myeloma patients; (B) gating for γδ T cells in healthy controls. - Increased CD8⁺ T cells (P < ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...